Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial
Authors
Diro, ERitmeijer, K
Boelaert, M
Alves, F
Mohammed, R
Abongomera, C
Ravinetto, R
De Crop, M
Fikre, H
Adera, C
van Loen, H
Tsoumanis, A
Adriaensen, W
Hailu, A
van Griensven, J
Issue Date
2017-09-13Submitted date
2017-10-18
Metadata
Show full item recordJournal
Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of AmericaAbstract
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation.Publisher
Oxford University PressPubMed ID
29020217Language
enISSN
1537-6591ae974a485f413a2113503eed53cd6c53
10.1093/cid/cix807
Scopus Count
Collections
Related articles
- Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
- Authors: Diro E, Edwards T, Ritmeijer K, Fikre H, Abongomera C, Kibret A, Bardonneau C, Soipei P, Mutinda B, Omollo R, van Griensven J, Zijlstra EE, Wasunna M, Alves F, Alvar J, Hailu A, Alexander N, Blesson S
- Issue date: 2019 Feb
- Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
- Authors: Diro E, Ritmeijer K, Boelaert M, Alves F, Mohammed R, Abongomera C, Ravinetto R, De Crop M, Fikre H, Adera C, Colebunders R, van Loen H, Menten J, Lynen L, Hailu A, van Griensven J
- Issue date: 2015
- <i>Leishmania</i> Antigenuria to Predict Initial Treatment Failure and Relapse in Visceral Leishmaniasis/HIV Coinfected Patients: An Exploratory Study Nested Within a Clinical Trial in Ethiopia.
- Authors: van Griensven J, Mengesha B, Mekonnen T, Fikre H, Takele Y, Adem E, Mohammed R, Ritmeijer K, Vogt F, Adriaensen W, Diro E
- Issue date: 2018
- The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
- Authors: Abongomera C, Diro E, Vogt F, Tsoumanis A, Mekonnen Z, Admassu H, Colebunders R, Mohammed R, Ritmeijer K, van Griensven J
- Issue date: 2017 Oct 30
- Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
- Authors: ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN
- Issue date: 2008 Jun 1